Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Anti-Tenascin Monoclonal Antibody I-Labeled 81C6 Via Surgically Created Cystic Resection Cavity in the Treatment of Patients With Primary Brain Tumors After External Beam Radiotherapy

NCT00003484 is registered in ClinicalTrials.gov with Darell D. Bigner, MD, PhD as lead sponsor.

NCT NCT00003484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Anti-Tenascin Monoclonal Antibody I-Labeled 81C6 Via Surgically Created Cystic Resection Cavity in the Treatment of Patients With Primary Brain Tumors After External Beam Radiotherapy
Lead sponsor
Darell D. Bigner, MD, PhD
Phase
Phase 1
Overall status
Completed
Start date
September 30, 1997
Completion date
March 31, 2010
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors, neuroblastoma